Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Enfortumab Vedotin With Pembrolizumab May Usher in New Standard for Treatment of Urothelial Carcinoma

April 13th 2023

Terence Friedlander, MD, discusses the significance of the FDA approval of enfortumab vedotin combined with pembrolizumab for patients with locally advanced or metastatic urothelial carcinoma, and expands on the data from the EV-103/KEYNOTE-869 trial that supported the approval.

Clinical Trial Data With Perioperative Therapy in MIBC: The RETAIN BLADDER Study

April 13th 2023

Focused discussion on the RETAIN BLADDER study, which explored the option to avoid cystectomy in patients with good response to systemic therapy.

Muscle-Invasive Bladder Cancer: Role of Minimal Residual Disease in Adjuvant Therapy

April 13th 2023

Continuing their discussion on adjuvant therapy in in muscle-invasive bladder cancer, panelists identify the utility of minimal residual disease testing.

Chemoimmunotherapy Is Associated With Tumor Downstaging in Urothelial Cancer

April 12th 2023

Neoadjuvant pembrolizumab plus gemcitabine with or without cisplatin led to high rates of downstaging to non–muscle invasive urothelial cancer in patients with muscle-invasive urothelial cancer, meeting the primary end points for both cohorts of the phase 1b/2 HCRN GU14-188 trial.

Erdafitinib Intravesical Delivery System Under Exploration in Select FGFR+ NMIBC or MIBC

April 10th 2023

Antoni Vilaseca, MD, PhD, explains the unique mechanism of the TAR-210 erdafitinib delivery system and expands on the key objectives, trial design, and patient characteristics of a phase 1 trial evaluating TAR-210 in patients with recurrent NMIBC or MIBC harboring select FGFR mutations or fusions.

Adjuvant Treatment Approaches in Muscle-Invasive Bladder Cancer

April 6th 2023

Centering discussion on several clinical trials, key opinion leaders reflect on the role of adjuvant therapy in muscle-invasive bladder cancer.

Evolving Neoadjuvant Treatment Strategies in Muscle-Invasive Bladder Cancer

April 6th 2023

Expert perspectives on the evolving role of neoadjuvant therapy in muscle-invasive bladder cancer (MIBC) with considerations for mainstay regimens.

Dr Daneshmand on the Investigation of Erdafitinib in NMIBC With FGFR2/3 Alterations

April 3rd 2023

Siamak Daneshmand, MD, discusses the rationale for investigating erdafitinib in patients with recurrent, intermediate-risk non–muscle invasive bladder cancer harboring FGFR3 or FGFR2 alterations.

Dr Ryan on the Implications of Updated Findings from JAVELIN Bladder 100 in Urothelial Cancer

April 3rd 2023

Christopher W. Ryan, MD, discusses the implications of updated findings from the phase 3 JAVELIN Bladder 100 trial in patients with locally advanced or metastatic urothelial cancer.

Dr. Friedlander on the FDA Approval of Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

April 3rd 2023

Terence Friedlander, MD, discusses the significance of the FDA approval of frontline enfortumab vedotin combined with pembrolizumab in patients with urothelial carcinoma.

FDA Approves Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma

April 3rd 2023

The FDA has granted accelerated approval to enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.

MIBC and mUC: Surgery, Systemic Therapy, and Bladder Preserving Treatments

March 30th 2023

Switching their focus to non-muscle-invasive bladder cancer (NMIBC), panelists identify the treatment armamentarium in this setting.

Novel Treatment Strategies in Non-Muscle Invasive Bladder Cancer

March 30th 2023

A bird’s eye view of treatment modalities in urothelial carcinoma covering systemic, surgical, and bladder preserving strategies.

How Many Lines of Therapy Are Patients Receiving for Urothelial Carcinoma?

March 23rd 2023

A brief review of sequencing patterns in urothelial carcinoma and the typical number of lines of therapy a patient may receive.

Overview of Practice Patterns in Urothelial Carcinoma

March 23rd 2023

A panel of four key opinion leaders share real-world urothelial carcinoma practice patterns at their respective institutions.

Erdafitinib Elicits Responses in High- and Intermediate-Risk NMIBC Harboring FGFR3/2 Alterations

March 22nd 2023

Siamak Daneshmand, MD, shed light on the phase 2 THOR-2 study evaluating different cohorts of patients with recurrent NMIBC, key findings from cohorts 2 and 3, and how ongoing research seeks to move the needle forward with novel drug delivery methods.

Maintenance Avelumab Plus Lurbinectedin Under Investigation in Metastatic Urothelial Carcinoma

March 17th 2023

Investigators are assessing the combination of avelumab and lurbinectedin as maintenance therapy for patients with metastatic urothelial carcinoma who achieve a response or stable disease following first-line, platinum-based chemotherapy in a single-arm phase 2 trial.

China’s NMPA Accepts BLA for Enfortumab Vedotin in Locally Advanced/Metastatic Urothelial Cancer

March 10th 2023

The Center for Drug Evaluation of the China National Medical Products Administration has accepted the biologics license application for enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer who received prior treatment with a PD-1/L1 inhibitor and platinum-based chemotherapy.

Extended Follow-up Results From CheckMate 274: Adjuvant Nivolumab in MIUC

March 10th 2023

Expert Matthew D. Galsky, MD, shares his perspective on follow-up results from CheckMate 274, which analyzed adjuvant nivolumab in patients with high-risk muscle-invasive urothelial carcinoma.

Updated CheckMate 274 Data Reaffirm Benefit of Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma

March 7th 2023

Matthew Galsky, MD, discusses the key long-term findings and the clinical implications of the updated data from the phase 3 CheckMate 274 trial of nivolumab for the adjuvant treatment of patients with urothelial carcinoma.